| IGTslow subjects Baseline | 2-year follow-up | IGTfast subjects Baseline | 2-year follow-up |
---|---|---|---|---|
n = (Female/Male) | 10 (4/6) | 12 (2/10) | ||
Serum | Â | Â | Â | Â |
HbA1c, % | 5.74 ± 0.13 | 5.38 ± 0.08* | 5.67 ± 0.11 | 5.33 ± 0.14** |
HOM A-IR | 3.52 ± 0.30 | 3.22 ± 0.51 | 5.23 ± 0.75 | 3.77 ± 0.71* |
ORAC, μmol | 56.0 ± 4.5 | 58.2 ± 3.1 | 54.0 ± 3.4 | 55.4 ± 3.2 |
P. carbonyl, arb.u. | 0.129 ± 0.005 | 0.126 ± 0.00 | 0.110 ± 0.003## | 0.106 ± 0.003* ## |
Uric acid, μmol/l | 370 ± 17 | 331 ± 18** | 379 ± 17 | 342 ± 21* |
Skeletal muscle | Â | Â | Â | Â |
P. carbonyl, arb.u. | 0.074 ± 0.011 | 0.071 ± 0.008 | 0.072 ± 0.007 | 0.070 ± 0.005 |
4-HNE, arb.u. | 0.29 ± 0.07 | 0.24 ± 0.04 | 0.25 ± 0.04 | 0.26 ± 0.04 |
Maximal oxygen uptake | Â | Â | Â | Â |
VO2max, l/min | 1.96 ± 0.22a | 2.10 ± 0.20* a | 2.52 ± 0.15 | 2.69± 0.15** |
VO2max, /weight ml/kg/min | 23.3 ± 2.7a | 25.3 ± 2.4* a | 28.2 ± 1.7 | 30.9 ± 1.6** |